Risankizumab injector study completed – no major breakthrough expected

NCT ID NCT06937619

Completed Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested how well the drug risankizumab (SKYRIZI) is absorbed when given through an on-body injector compared to a standard injection. It involved 263 healthy adults and measured drug levels in the blood and any side effects. The goal was to see if the on-body injector delivers the drug similarly to the usual method, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Risankizumab (SKYRIZI)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Acpru /Id# 271954

Grayslake, Illinois, 60030, United States
CenExel ACT- Anaheim Clinical Trials /ID# 274805

Anaheim, California, 92801, United States
Collaborative Neuroscience Research CNS /ID# 275212

Los Alamitos, California, 90720, United States
Cpmi /Id# 274464

Miami, Florida, 33172, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.